Drugs / AMG 900
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01380756 | Oct 2011 → Sep 2014 | acute myeloid leukemia | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00858377 | Aug 2009 → Dec 2014 | cancer | Amgen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 900 | “AMG 900 is an investigational, oral, selective pan-Aurora kinase inhibitor.” PMID 29980894 ↗ Jul 20181“AMG 900 is a small molecule aurora kinase inhibitor.” NCT01380756 ↗ |
| Known as | AMG 18 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2140408 ↗ |
| Action | Inhibit | “AMG 900 is a small molecule inhibitor of aurora kinases A, B and C.” NCT00858377 ↗ |
| Modality | Small molecule | “AMG 900 is a small molecule inhibitor of aurora kinases A, B and C.” NCT00858377 ↗ |
| Route | Oral | “oral AMG 900” NCT01380756 ↗ |